The relationship between immunodominance, DM editing, and the kinetic stability of MHC class II:peptide complexes

Immunological Reviews

Volumn 207, Issue , 2005, Pages 261-278

  Sant, Andrea J ^a   Chaves, Francisco A ^a   Jenks, Scott A ^a   Richards, Katherine A ^a   Menges, Paula ^a   Weaver, J M ^a   Lazarski, Christopher A ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA DM ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; LYMPHOCYTE DIFFERENTIATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN STABILITY; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; CD4-POSITIVE T-LYMPHOCYTES; HLA-D ANTIGENS; HUMANS; IMMUNODOMINANT EPITOPES; MODELS, IMMUNOLOGICAL; PEPTIDES;

EID: 22544482556     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0105-2896.2005.00307.x     Document Type: Review

References (164)

1. Berkower I, Kawamura H, Matis LA, Berzofsky JA. T cell clones to two major T cell epitopes of myoglobin: effect of I-A/I-E restriction on epitope dominance. J Immunol 1985;135:2628-2634.
2. Schaeffer EB, et al. Relative contribution of 'determinant selection' and 'holes in the T-cell repertoire' to T-cell responses. Proc Natl Acad Sci USA 1989;86:4649-4653.
3. Sercarz EE, Lehmann PV, Ametani A, Benichou G, Miller A, Moudgil K. Dominance and crypticity of T cell antigenic determinants. Annu Rev Immunol 1993;11:729-766.
4. Deng H, Fosdick L, Sercarz E. The involvement of antigen processing in determinant selection by class II MHC and its relationship to immunodominance. APMIS 1993;101:655-662.
5. Fairchild PJ. Reversal of immunodominance among autoantigenic T-cell epitopes. Autoimmunity 1999;30:209-221.
6. Blum JS, Ma C, Kovats S. Antigen-presenting cells and the selection of immunodominant epitopes. Crit Rev Immunol 1997;17:411-417.
7. b mice. J Immunol 1999;163:2549-2554.
8. Ma C, et al. Role of APC in the selection of immunodominant T cell epitopes. J Immunol 1999;163:6413-6423.
9. Moudgil KD, Sercarz EE, Grewal IS. Modulation of the immunogenicity of antigenic determinants by their flanking residues. Immunol Today 1998;19:217-220.
10. Gapin L, Cabaniols JP, Cibotti R, Ojcius DM, Kourilsky P, Kanellopoulos JM. Determinant selection for T-cell tolerance in HEL-transgenic mice: dissociation between immunogenicity and tolerogenicity. Cell Immunol 1997;177:77-85.
11. Yewdell JW, Bennink JR. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol 1999;17:51-88.
12. Safley SA, Jensen PE, Reay PA, Ziegler HK. Mechanisms of T cell epitope immunodominance analyzed in murine listeriosis. J Immunol 1995;155:4355-4366.
13. Moudgil KD, Deng H, Nanda NK, Grewal IS, Ametani A, Sercarz EE. Antigen processing and T cell repertoires as crucial aleatory features in induction of autoimmunity. J Autoimmun 1996;9:227-234.
14. Adorini L, Muller S, Cardinaux F, Lehmann PV, Falcioni F, Nagy ZA. In vivo competition between self peptides and foreign antigens in T-cell activation. Nature 1988;334:623-625.
15. Nikcevich KM, Kopielski D, Finnegan A. Interference with the binding of a naturally processed peptide to class II alters the immunodominance of T cell epitopes in vivo. J Immunol 1994;153:1015-1026.
16. Liu Z, Williams KP, Chang YH, Smith JA. Immunodominance: a single amino acid substitution within an antigenic site alters intramolecular selection of T cell determinants. J Immunol 1993;151:1852-1858.
17. Chicz RM, Urban RG, Gorga JC, Vignali DA, Lane WS, Strominger JL. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med 1993;178:27-47.
18. Hunt DF, et al. Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad. Science 1992;256:1817-1820.
19. Kedl RM, Kappler JW, Marrack P. Epitope dominance, competition and T cell affinity maturation. Curr Opin Immunol 2003;15:120-127.
20. McHeyzer-Williams LJ, Panus JF, Mikszta JA, McHeyzer-Williams MG. Evolution of antigen-specific T cell receptors in vivo: preimmune and antigen-driven selection of preferred complementarity-determining region 3 (CDR3) motifs. J Exp Med 1999;189:1823-1838.
21. McHeyzer-Williams MG, Altman JD, Davis MM. Tracking antigen-specific helper T cell responses. Curr Opin Immunol 1996;8:278-284.
22. Fasso M, Anandasabapathy N, Crawford F, Kappler J, Fathman CG, Ridgway WM. T cell receptor (TCR)-mediated repertoire selection and loss of TCR vbeta diversity during the initiation of a CD4(+) T cell response in vivo. J Exp Med 2000;192:1719-1730.
23. Jensen PE, Weber DA, Thayer WP, Chen X, Dao CT. HLA-DM and the MHC class II antigen presentation pathway. Immunol Res 1999;20:195-205.
24. Vogt AB, Kropshofer H, Hammerling GJ. How HLA-DM affects the peptide repertoire bound to HLA-DR molecules. Hum Immunol 1997;54:170-179.
25. Alfonso C, Karlsson L. Nonclass MHC class II molecules. Annu Rev Immunol 2000;18:113-142.
26. Kropshofer H, Hammerling GJ, Vogt AB. The impact of the non-classical MHC proteins HLA-DM and HLA-DO on loading of MHC class II molecules. Immunol Rev 1999;172:267-278.
27. Busch R, Mellins ED. Developing and shedding inhibitions: how MHC class II molecules reach maturity. Curr Opin Immunol 1996;8:51-58.
28. Denzin LK, Cresswell P. HLA-DM induces CLIP dissociation from MHC class II alpha beta dimers and facilitates peptide loading. Cell 1995;82:155-165.
29. Sherman MA, Weber DA, Jensen PE. DM enhances peptide binding to class II MHC by release of invariant chain-derived peptide. Immunity 1995;3:197-205.
30. Weber DA, Evavold BD, Jensen PE. Enhanced dissociation of HLA-DR-bound peptides in the presence of HLA-DM. Science 1996;274:618-620.
31. Sloan VS, et al. Mediation by HLA-DM of dissociation of peptides from HLA-DR. Nature 1995;375:802-806.
32. Belmares MP, Busch R, Wucherpfennig KW, McConnell HM, Mellins ED. Structural factors contributing to DM susceptibility of MHC class II/peptide complexes. J Immunol 2002;169:5109-5117.
33. van Ham SM, Gruneberg U, Malcherek G, Broker I, Melms A, Trowsdale J. Human histocompatibility leukocyte antigen (HLA)-DM edits peptides presented by HLA-DR according to their ligand binding motifs. J Exp Med 1996;:184:2019-2024.
34. Stebbins CC, Loss GE Jr, Elias CG, Chervonsky A, Sant AJ. The requirement for DM in class II-restricted antigen presentation and SDS-stable dimer formation is allele and species dependent. J Exp Med 1995;181:223-234.
35. Stebbins CC, Peterson ME, Suh WM, Sant AJ. DM-mediated release of a naturally occurring invariant chain degradation intermediate from MHC class II molecules. J Immunol 1996;157:4892-4898.
36. Mellins E, Kempin S, Smith L, Monji T, Pious D. A gene required for class II-restricted antigen presentation maps to the major histocompatibility complex. J Exp Med 1991;174:1607-1615.
37. Pinet V, Malnati MS, Long EO. Two processing pathways for the MHC class II-restricted presentation of exogenous influenza virus antigen. J Immunol 1994;152:4852-4860.
38. Lovitch SB, Petzold SJ, Unanue ER. Cutting edge: H-2DM is responsible for the large differences in presentation among peptides selected by I-Ak during antigen processing. J Immunol 2003;171:2183-2186.
39. Bikoff EK, Wutz G, Kenty GA, Koonce CH, Robertson EJ. Relaxed DM requirements during class II peptide loading and CD4+ T cell maturation in BALB/c mice. J Immunol 2001;166:5087-5098.
40. k class II molecules in human APC containing deleted or mutated HLA DM genes. J Immunol 1994;153:5382-5392.
41. Koonce CH, Wutz G, Robertson EJ, Vogt AB, Kropshofer H, Bikoff EK. DM loss in k haplotype mice reveals isotype-specific chaperone requirements. J Immunol 2003;170:3751-3761.
42. Wolf PR, Tourne S, Miyazaki T, Benoist C, Matnis D, Ploegh HL. The phenotype of H-2M-deficient mice is dependent on the MHC class II molecules expressed. Eur J Immunol 1998;28:2605-2618.
43. Weenink S, et al. Impaired antigen presentation by murine I-Ad class II MHC molecules expressed in normal and HLA-DM-defective human B cell lines. Int Immunol 1997;9:889-896.
44. Albert LJ, Ghumman B, Watts TH. Effect of HLA-DM transfection on hen egg lysozyme presentation by T2.Ak cells. J Immunol 1996;157:2247-2255.
45. Miyazaki T, et al. Mice lacking H2-M complexes, enigmatic elements of the MHC class II peptide-loading pathway. Cell 1996;84:531-541.
46. Vogt AB, Arndt SO, Hammerling GJ, Kropshofer H. Quality control of MHC class II associated peptides by HLA-DM/H2-M. Semin Immunol 1999;11:391-403.
47. Sahara H, Shastri N. Second class minors: molecular identification of the autosomal H46 histocompatibility locus as a peptide presented by major histocompatibility complex class II molecules. J Exp Med 2003;197:375-385.
48. Malnati MS, et al. Processing pathways for presentation of cytosolic antigen to MHC class II-restricted T cells. Nature 1992;357:702-704.
49. Paludan C, et al. Endogenous MHC class II processing of a viral nuclear antigen after autophagy. Science 2005;307:593-596.
50. Calin-Laurens V, et al. High efficiency of endogenous antigen presentation by MHC class II molecules. Int Immunol 1992;4:1113-1121.
51. Brooks A, et al. Class II-restricted presentation of an endogenously derived immunodominant T-cell determinant of hen egg lysozyme. Proc Natl Acad Sci USA 1991;88:3290-3294.
52. Sant AJ. Endogenous antigen presentation by MHC class II molecules. Immunol Res 1994;13:253-267.
53. Parra-Lopez CA, Lindner R, Vidavsky I, Gross M, Unanue ER. Presentation on class II MHC molecules of endogenous lysozyme targeted to the endocytic pathway. J Immunol 1997;158:2670-2679.
54. Oxenius A, Bachmann MF, Ashton-Rickardt PG, Tonegawa S, Zinkernagel RM, Hengartner H. Presentation of endogenous viral proteins in association with major histocompatibility complex class II: on the role of intracellular compartmentalization, invariant chain and the TAP transporter system. Eur J Immunol 1995;25:3402-3411.
55. Loss GE Jr, Elias CG, Fields PE, Ribaudo RK, McKisic M, Sant AJ. Major histocompatibility complex class II-restricted presentation of an internally synthesized antigen displays cell-type variability and segregates from the exogenous class II and endogenous class I presentation pathways. J Exp Med 1993;178:73-85.
56. Qi L, Ostrand-Rosenberg S. H2-O inhibits presentation of bacterial superantigens, but not endogenous self antigens. J Immunol 2001;167:1371-1378.
57. Kovats S, et al. Invariant chain-independent function of H-2M in the formation of endogenous peptide-major histocompatibility complex class II complexes in vivo. J Exp Med 1998;187:245-251.
58. Lightstone L, et al. In the absence of the invariant chain, HLA-DR molecules display a distinct array of peptides which is influenced by the presence or absence of HLA-DM. Proc Natl Acad Sci USA 1997;94:5772-5777.
59. Katz JF, Stebbins C, Appella E, Sant AJ. Invariant chain and DM edit self-peptide presentation by major histocompatibility complex (MHC) class II molecules. J Exp Med 1996;184:1747-1753.
60. Karlsson L, Peleraux A, Lindstedt R, Liljedahl M, Peterson PA. Reconstitution of an operational MHC class II compartment in nonantigen-presenting cells. Science 1994;266:1569-1573.
61. Morris P, et al. An essential role for HLA-DM in antigen presentation by class II major histocompatibility molecules. Nature 1994;368:551-554.
62. Martin WD, Hicks GG, Mendiratta SK, Leva HI, Ruley HE, Van Kaer L. H2-M mutant mice are defective in the peptide loading of class II molecules, antigen presentation, and T cell repertoire selection. Cell 1996;84:543-550.
63. Fling SP, Arp B, Pious D. HLA-DMA and -DMB genes are both required for MHC class II/peptide complex formation in antigen-presenting cells. Nature 1994;368:554-558.
64. Lich JD, Jayne JA, Zhou D, Elliott JF, Blum JS. Editing of an immunodominant epitope of glutamate decarboxylase by HLA-DM. J Immunol 2003;171:853-859.
65. Pathak SS, Lich JD, Blum JS. Cutting edge: editing of recycling class II:peptide complexes by HLA-DM. J Immunol 2001;167:632-635.
66. Raddrizzani L, et al. Identification of destabilizing residues in HLA class II-selected bacteriophage display libraries edited by HLA-DM. Eur J Immunol 1999;29:660-668.
67. Kropshofer H, Vogt AB, Moldenhauer G, Hammer J, Blum JS, Hammerling GJ. Editing of the HLA-DR-peptide repertoire by HLA-DM. EMBO J 1996;15:6144-6154.
68. Muntasell A, et al. Dissection of the HLA-DR4 peptide repertoire in endocrine epithelial cells: strong influence of invariant chain and HLA-DM expression on the nature of ligands. J Immunol 2004;173:1085-1093.
69. Nanda NK, Sant AJ. DM determines the cryptic and immunodominant fate of T cell epitopes. J Exp Med 2000;192:781-788.
70. Manoury B, et al. Destructive processing by asparagine endopeptidase limits presentation of a dominant T cell epitope in MBP. Nat Immunol 2002;3:169-174 (see comment).
71. Gapin L, Bravo de Alba Y, Casrouge A, Cabaniols JP, Kourilsky P, Kanellopoulos J. Antigen presentation by dendritic cells focuses T cell responses against immunodominant peptides: studies in the hen eggwhite lysozyme (HEL) model. J Immunol 1998;160:1555-1564.
72. Schneider SC, et al. Cutting edge: introduction of an endopeptidase cleavage motif into a determinant flanking region of hen egg lysozyme results in enhanced T cell determinant display. J Immunol 2000;165:20-23.
73. Brett SJ, Cease KB, Berzofsky JA. Influences of antigen processing on the expression of the T cell repertoire. Evidence for MHC-specific hindering structures on the products of processing. J Exp Med 1988;168:357-373.
74. Godkin AJ, et al. Naturally processed HLA class II peptides reveal highly conserved immunogenic flanking region sequence preferences that reflect antigen processing rather than peptide-MHC interactions. J Immunol 2001;166:6720-6727.
75. Lo-Man R, Martineau P, Betton JM, Hofnung M, Leclerc C. Molecular context of a viral T cell determinant within a chimeric bacterial protein alters the diversity of its T cell recognition. J Immunol 1994;152:5660-5669.
76. Lazarski CA, et al. Kinetic stability of MHC class II: peptide complexes is a key parameter that dictates immunodominance. Immunity (in press).
77. Wettstein DA, Boniface JJ, Reay PA, Schild H, Davis MM. Expression of a class II major histocompatibility complex (MHC) heterodimer in a lipid-linked form with enhanced peptide/soluble MHC complex formation at low pH. J Exp Med 1991;174:219-228.
78. d MHC class II molecules with I-E-derived sequences promotes production of an active and stable soluble heterodimer without altering peptide-binding specificity. J Immunol Methods 2005;300:74-92.
79. Martineau P, Guillet JG, Leclerc C, Hofhung M. Expression of heterologous peptides at two permissive sites of the MalE protein: antigenicity and immunogenicity of foreign B-cell and T-cell epitopes. Gene 1992;118:151
80. [erratum for Gene 1992;113:35-46].
81. Lo-Man R, Langeveld JP, Martineau P, Hofnung M, Meloen RH, Leclerc C. Immunodominance does not result from peptide competition for MHC class II presentation. J Immunol 1998;160:1759-1766.
82. Lo-Man R, Martineau P, Hofhung M, Leclerc C. Induction of T cell responses by chimeric bacterial proteins expressing several copies of a viral T cell epitope. Eur J Immunol 1993;23:2998-3002.
83. Carson RT, Vignali KM, Woodland DL, Vignali DA. T cell receptor recognition of MHC class II-bound peptide flanking residues enhances immunogenicity and results in altered TCR V region usage. Immunity 1997;7:387-399.
84. Arnold PY, et al. The majority of immunogenic epitopes generate CD4 + T cells that are dependent on MHC class II-bound peptide-flanking residues. J Immunol 2002;169:739-749
85. [erratum appears in J Immunol 2002;169:4674].
86. Zavala-Ruiz Z, Strug I, Walker BD, Norris PJ, Stern LJ. A hairpin turn in a class II MHC-bound peptide orients residues outside the binding groove for T cell recognition. Proc Natl Acad Sci USA 2004;101:13279-13284.
87. Berkower I, Matis LA, Buckenmeyer GK, Gurd FR, Longo DL, Berzofsky JA. Identification of distinct predominant epitopes recognized by myoglobin-specific T cells under the control of different Ir genes and characterization of representative T cell clones. J Immunol 1984;132:1370-1378.
88. Moudgil KD, Sekiguchi D, Kim SY, Sercarz EE. Immunodominance is independent of structural constraints: each region within hen eggwhite lysozyme is potentially available upon processing of native antigen. J Immunol 1997;159:2574-2579.
89. Mougneau E, et al. Expression cloning of a protective Leishmania antigen. Science 1995;268:563-566.
90. Scott CA, Peterson PA, Teyton L, Wilson IA. Crystal structures of two I-Ad-peptide complexes reveal that high affinity can be achieved without large anchor residues. Immunity 1998;8:319-329
91. [erratum appears in Immunity 1998;8:531].
92. McFarland BJ, Katz JF, Beeson C, Sant AJ. Energetic asymmetry among hydrogen bonds in MHC class II*peptide complexes. Proc Natl Acad Sci USA 2001;98:9231-9236.
93. Reiner S, Wang Z, Hatam F, Scott P, Locksley RM. Th1 and Th2 cell antigen receptors in experimental Leishmaniasis. Science 1993;259:1457-1460.
94. Milon G, Titus RG, Cerottini JC, Marchal G, Louis JA. Higher frequency of Leishmania major-specific L3T4+ T cells in susceptible BALB/c as compared with resistant CBA mice. J Immunol 1986;136:1467-1471.
95. Stetson DB, Mohrs M, Mallet-Designe V, Teyton L, Locksley RM. Rapid expansion and IL-4 expression by Leishmania-specific naive helper T cells in vivo. Immunity 2002;17:191-200.
96. Jenkins MK, et al. In vivo activation of antigen-specific CD4 T cells. Annu Rev Immunol 2001;19:23-45.
97. Garside P, Ingulli E, Merica RR, Johnson JG, Noelle RJ, Jenkins MK. Visualization of specific B and T lymphocyte interactions in the lymph node. Science 1998;281:96-99.
98. Ingulli E, Ulman DR, Lucido MM, Jenkins MK. In situ analysis reveals physical interactions between CD11b+ dendritic cells and antigen-specific CD4 T cells after subcutaneous injection of antigen. J Immunol 2002;169:2247-2252.
99. Robertson JM, Jensen PE, Evavold BD. DO11.10 and OT-II T cells recognize a C-terminal ovalbumin 323-339 epitope. J Immunol 2000;164:4706-4712.
100. McFarland BJ, Sant AJ, Lybrand TP, Beeson C. Ovalbumin (323-339) peptide binds to the major histocompatibility complex class II, I-A(d) protein using two functionally distinct registers. Biochemistry 1999;38: 16663-16670.
101. Kersh GJ, et al. Structural and functional consequences of altering a peptide MHC anchor residue. J Immunol 2001;166:3345-3354.
102. Ryan KR, McNeil LK, Dao C, Jensen PE, Evavold BD. Modification of peptide interaction with MHC creates TCR partial agonists. Cell Immunol 2004;227:70-78.
103. Ford ML, Evavold BD. Degenerate recognition of T cell epitopes: impact of T cell receptor reserve and stability of peptide:MHC complexes. Mol Immunol 2004;40:1019-1025.
104. Mirshahidi S, Ferris LC, Sadegh-Nasseri S. The magnitude of TCR engagement is a critical predictor of T cell anergy or activation. J Immunol 2004;172:5346-5355.
105. Denzin LK, Hammond C, Cresswell P. HLA-DM interactions with intermediates in HLA-DR maturation and a role for HLA-DM in stabilizing empty HLA-DR molecules. J Exp Med 1996;184:2153-2165.
106. Chou CL, Sadegh-Nasseri S. HLA-DM recognizes the flexible conformation of major histocompatibility complex class II. J Exp Med 2000;192:1697-1706.
107. Stratikos E, Wiley DC, Stern LJ. Enhanced catalytic action of HLA-DM on the exchange of peptides lacking backbone hydrogen bonds between their N-terminal region and the MHC class II alpha-chain. J Immunol 2004;172:1109-1117.
108. Sant AJ, et al. Individual hydrogen bonds play a critical role in MHC class II: peptide interactions: implications for the dynamic aspects of class II trafficking and DM-mediated peptide exchange. Immunol Rev 1999;172:239-253.
109. Vogt AB, Kropshofer H, Moldenhauer G, Hammerling GJ. Kinetic analysis of peptide loading onto HLA-DR molecules mediated by HLA-DM. Proc Natl Acad Sci USA 1996;93:9724-9729.
110. Kedl RM, et al. T cells compete for access to antigen-bearing antigen-presenting cells. J Exp Med 2000;192:1105-1113.
111. Rees W, et al. An inverse relationship between T cell receptor affinity and antigen dose during CD4(+) T cell responses in vivo and in vitro. Proc Natl Acad Sci USA 1999;96:9781-9786.
112. Smith AL, Wikstrom ME, Fazekas de St Groth B. Visualizing T cell competition for peptide/MHC complexes: a specific mechanism to minimize die effect of precursor frequency. Immunity 2000;13:783-794.
113. Borghans JA, Taams LS, Wauben MH, de Boer RJ. Competition for antigenic sites during T cell proliferation: a mathematical interpretation of in vitro data. Proc Natl Acad Sci USA 1999;96:10782-10787.
114. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 2002;20:621-667.
115. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-252.
116. Mempel TR, Henrickson SE, Von Andrian UH. T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature 2004;427:154-159.
117. Cyster JG. Chemokines and the homing of dendritic cells to the T cell areas of lymphoid organs. J Exp Med 1999;189:447-450 (comment).
118. MartIn-Fontecha A, et al. Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med 2003;198:615-621.
119. Schrum AG, Turka LA. The proliferative capacity of individual naive CD4(+) T cells is amplified by prolonged T cell antigen receptor triggering. J Exp Med 2002;196:793-803.
120. Gett AV, Sallusto F, Lanzavecchia A, Geginat J. T cell fitness determined by signal strength. Nat Immunol 2003;4:355-360.
121. Miller MJ, Hejazi AS, Wei SH, Cahalan MD, Parker I. T cell repertoire scanning is promoted by dynamic dendritic cell behavior and random T cell motility in the lymph node. Proc Natl Acad Sci USA 2004;101:998-1003.
122. Itano AA, Jenkins MK. Antigen presentation to naive CD4 T cells in the lymph node. Nat Immunol 2003;4:733-739.
123. Lanzavecchia A, Sallusto F. Progressive differentiation and selection of the fittest in the immune response. Nat Rev Immunol 2002;2:982-987.
124. Lanzavecchia A, Sallusto F. Antigen decoding by T lymphocytes: from synapses to fate determination. Nat Immunol 2001;2:487-492.
125. Huppa JB, Gleimer M, Sumen C, Davis MM. Continuous T cell receptor signaling required for synapse maintenance and full effector potential. Nat Immunol 2003;4:749-755.
126. Iezzi G, Karjalainen K, Lanzavecchia A. The duration of antigenic stimulation determines the fate of naive and effector T cells. Immunity 1998;8:89-95.
127. Miller MJ, Safrina O, Parker I, Cahalan MD. Imaging the single cell dynamics of CD4 + T cell activation by dendritic cells in lymph nodes. J Exp Med 2004;200:847-856.
128. Reijonen H, Kwok WW. Use of HLA class II tetramers in tracking antigen-specific T cells and mapping T-cell epitopes. Methods (Duluth) 2003;29:282-288.
129. Kyewski B, Derbinski J. Self-representation in the thymus: an extended view. Nat Rev Immunol 2004;4:688-698.
130. Anderson MS, et al. Projection of an immunological self shadow within the thymus by the aire protein. Science 2002;298: 1395-1401.
131. Hanahan D. Peripheral-antigen-expressing cells in thymic medulla: factors in self-tolerance and autoimmunity. Curr Opin Immunol 1998;10:656-662.
132. Gotter J, Kyewski B. Regulating self-tolerance by deregulating gene expression. Curr Opin Immunol 2004;16:741-745.
133. Derbinski J, Schulte A, Kyewski B, Klein L. Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self. Nat Immunol 2001;2:1032-1039.
134. Venanzi ES, Benoist C, Mathis D. Good riddance: thymocyte clonal deletion prevents autoimmunity. Curr Opin Immunol 2004;16:197-202.
135. Gebe JA, et al. Low-avidity recognition by CD4+ T cells directed to self-antigens. Eur J Immunol 2003;33:1409-1417.
136. Liu GY, Fairchild PJ, Smith RM, Prowle JR, Kioussis D, Wraith DC. Low avidity recognition of self-antigen by T cells permits escape from central tolerance. Immunity 1995;3:407-415.
137. Targoni OS, Lehmann PV. Endogenous myelin basic protein inactivates the high avidity T cell repertoire. J Exp Med 1998;187:2055-2063.
138. Cibotti R, et al. Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants. Proc Natl Acad Sci USA 1992;89:416-420.
139. Fairchild PJ, Wraith DC. Lowering the tone: mechanisms of immunodominance among epitopes with low affinity for MHC. Immunol Today 1996;17:80-85.
140. Harrington CJ, et al. Differential tolerance is induced in T cells recognizing distinct epitopes of myelin basic protein. Immunity 1998;8:571-580.
141. Wucherpfennig KW. Autoimmunity in the central nervous system: mechanisms of antigen presentation and recognition. Clin Immunol Immunopathol 1994;72:293-306.
142. Williams CB, Engle DL, Kersh GJ, Michael White J, Allen PM. A kinetic threshold between negative and positive selection based on the longevity of the T cell receptor-ligand complex. J Exp Med 1999;:189:1531-1544.
143. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR. T cell receptor antagonist peptides induce positive selection. Cell 1994;76:17-27.
144. Wang R, Nelson A, Kimachi K, Grey HM, Farr AG. The role of peptides in thymic positive selection of class II major histocompatibility complex-restricted T cells. Proc Natl Acad Sci USA 1998;95:3804-3809.
145. Stefanski HE, Mayerova D, Jameson SC, Hogquist KA. A low affinity TCR ligand restores positive selection of CD8+ T cells in vivo. J Immunol 2001;166:6602-6607
146. [erratum appears in J Immunol 2001;167:593].
147. Holmberg K, Mariathasan S, Ohteki T, Ohashi PS, Gascoigne NR. TCR binding kinetics measured with MHC class I tetramers reveal a positive selecting peptide with relatively high affinity for TCR. J Immunol 2003;171:2427-2434.
148. Vidard L, Rock KL, Benacerraf B. The generation of immunogenic peptides can be selectively increased or decreased by proteolytic enzyme inhibitors. J Immunol 1991;147:1786-1791.
149. Nelson CA, Viner NJ, Unanue ER. Appreciating the complexity of MHC class II peptide binding: lysozyme peptide and I-Ak. Immunol Rev 1996;151:81-105.
150. DiPaolo RJ, Unanue ER. Cutting edge: chemical dominance does not relate to immunodominance: studies of the CD4 + T cell response to a model antigen. J Immunol 2002;169:1-4.
151. Moudgil KD, Wang J, Yeung VP, Sercarz EE. Heterogeneity of the T cell response to immunodominant determinants within hen eggwhite lysozyme of individual syngeneic hybrid F1 mice: implications for autoimmunity and infection. J Immunol 1998;161:6046-6053.
152. Gammon G, et al. T cell determinant structure: cores and determinant envelopes in three mouse major histocompatibility complex haplotypes. J Exp Med 1991;173:609-617.
153. Dai G, Carmicle S, Steede NK, Landry SJ. Structural basis for helper T-cell and antibody epitope immunodominance in bacteriophage T4 Hsp10. Role of disordered loops. J Biol Chem 2002;277:161-168.
154. Phan UT, Arunachalam B, Cresswell P. Gamma-interferon-inducible lysosomal thiol reductase (GILT). Maturation, activity, and mechanism of action. J Biol Chem 2000;275:25907-25914.
155. Wlodawer A, Bott R, Sjolin L. The refined crystal structure of ribonuclease A at 2.0 A resolution. J Biol Chem 1982;257:1325-1332.
156. Landry SJ. Helper T-cell epitope immunodominance associated with structurally stable segments of hen egg lysozyme and HIV gp120. J Theor Biol 2000;203:189-201.
157. Delamarre L, Pack M, Chang H, Mellman I, Trombetta ES. Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science 2005;307:1630-1634.
158. Watts C. Antigen processing in the endocytic compartment. Curr Opin Immunol 2001;13:26-31.
159. Medd PG, Chain BM. Protein degradation in MHC class II antigen presentation: opportunities for immunomodulation. Semin Cell Dev Biol 2000;11:203-210.
160. Honey K, Rudensky AY. Lysosomal cysteine proteases regulate antigen presentation. Nat Rev Immunol 2003;3:472-482.
161. Lennon-Dumenil AM, Bakker AH, Wolf-Bryant P, Ploegh HL, Lagaudriere-Gesbert C. A closer look at proteolysis and MHC-class-II-restricted antigen presentation. Curr Opin Immunol 2002;14:15-21.
162. McGrath ME. The lysosomal cysteine proteases. Annu Rev Biophys Biomol Struct 1999;28:181-204.
163. Gerhard W, Haberman AM, Scherle PA, Taylor AH, Palladino G, Caton AJ. Identification of eight determinants in the hemagglutinin molecule of influenza virus A/PR/8/34 (H1N1) which are recognized by class II-restricted T cells from BALB/c mice. J Virol 1991;65:364-372.
164. Sette A, Fikes J. Epitope-based vaccines: an update on epitope identification, vaccine design and delivery. Curr Opin Immunol 2003;15:461-470.